Skip to main content
Mario Eisenberger, MD, Oncology, Baltimore, MD, Johns Hopkins Hospital

MarioAlfredoEisenbergerMD

Oncology • Baltimore, MD

Genitourinary Oncology

R.Dale Hughes Professor of Oncology, Professor of Urology, Johns Hopkins University School of Medicine;

Join to view full profile

Dr. Eisenberger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Eisenberger's full profile

Already have an account?

  • Office

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone+1 410-614-3511
  • Is this information wrong?

Summary

  • Professor of Oncology and Urology

Education & Training

  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 1976 - 1978
  • Michael Reese Hospital and Medical Center
    Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1973 - 1975
  • Faculdade de Medicina da Universidade Federal do Rio de Janeiro
    Faculdade de Medicina da Universidade Federal do Rio de JaneiroClass of 1972
  • Brazil-American College
    Brazil-American CollegeB.S., Cum Laude, 1965 - 1966
  • Mello E. Souza College
    Mello E. Souza CollegeNo Degree, 1963 - 1965

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1982 - 2024
  • PA State Medical License
    PA State Medical License 2020 - 2022
  • DC State Medical License
    DC State Medical License 2012 - 2020
  • IL State Medical License
    IL State Medical License 1975 - 1980
  • FL State Medical License
    FL State Medical License 1978 - 1979
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Prostate Cancer Challenge Award Prostate Cancer Foundation, 2015
  • America's Top Doctors Castle Connolly, 2003-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer  
    Emmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
  • Original Contribution TP53 Missense Mutation Is Associated with Increased Tumor-Infiltrating T-cells in Primary Prostate Cancer☆  
    Tamara L Lotan, Mario Eisenberger, Harsimar B Kaur, Scott A Tomlins, Edward M Schaeffer, ScienceDirect
  • Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years Progress with Antiandrogens  
    Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F, The Journal of Urology, 1/1/2018
  • Join now to see all

Books/Book Chapters

  • Current Clinical Oncology: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies 
    Chapter: The Current Knowledge of Hormonal Therapy in the Treatment of Prostate Cancer 
    Eisenberger MA2007
  • Prostate Cancer 
    Chapter: Committee 13, new therapeutic targets and treatments for metastatic prostate cancer. 
    Nelson, W.G., Saad, F., Debruyne, F.M.J., Eisenberger, M.A., Fourcade, R., Frenkel, E.P., Kantoff, P.W., Kumon, H., Nasu, Y., Oudard, S., and Wirth, M.Editors: McConnell, J., Denis, L., Akaza, H., Khoury, S., and Schalken, J..Health Publications, Paris, France2006
  • Prostate Cancer, Principles & Practice 
    Chapter: Controversies in hormone treatment for prostate cancer. 
    Eisenberger MANartub Dybutz Ktd (Taylor & Francis Group)2005
  • Join now to see all

Abstracts/Posters

  • Characteristics and outcome of octogenarian versus young patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with ketoconazole.
    V.J. Sinibaldi, M. Dadon-Nachum, M. Gottfried, N. Maimon, Z. Dovrish, A. Peer, A. Neumann, A. Sella, S. Kovel, M.A. Carducci, M.A. Eisenberger, D. Keizman, Genitourinary Cancers Symposium, 1/1/2014
  • A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC).
    M.T. Schweizer, E.S. Antonarakis, H. Wang, A.N. Spitz, H.Cao, A. Pacheo, M.A. Eisenberger, M.A. Carducci, S.R. Denmeade, Genitourinary Cancers Symposium, 1/1/2014
  • A phase I trial of muscadine grape skin in men with biochemically recurrent prostate cancer.
    C.J. Paller, M.A. Rudek, E.S. Antonarakis, M.A. Eisenberger, H.J. Hammers, X.C. Zhou, D. Dowling, S. King, S. Hudock, S.R. Denmeade, W.D. Wagner, G.L. Rosner, T. Hudso..., Genitourinary Cancers Symposium, 1/1/2014
  • Join now to see all

Lectures

  • Selected Aspects in the management and treatment of Relapsed Prostate Cancer. 
    University of Maryland Cancer Center - 1/1/2016
  • Advances in Hormonal therapy for prostate cancer and optimal timing for androgen deprivation. 
    1/1/2016
  • Biomarkers in Prostate Cancer 
    Boston, MA - 1/1/2015
  • Join now to see all

Other

  • Chemotherapy for prostate cancer. 
    Eisenberger MA, Plenary Session Debate-European Association of Urology
    Milan, Italy - 1/1/2007
  • Therapeutic strategies for patients with a rising PSA: A case-based approach. Report to the Nation on Prostate Cancer 2004. 
    D'Amico AV, Eisenberger MA, Partin AW, Pienta KJ, Prostate Cancer Foundation (pp. 85-92)
    1/1/2004
  • Hormonal Therapy for Advanced Prostate Cancer. 
    Eisenberger, M, The Johns Hopkins White Paper Bulletins, Prostate Bulletin Winter Issue (pp. 23-32)
    1/23/2002
  • Join now to see all

Press Mentions

  • Reduced-Dose Cabazitaxel Shows Efficacy in mCRPC
    Reduced-Dose Cabazitaxel Shows Efficacy in mCRPCAugust 25th, 2017
  • The Female Health Company and Aspen Park Pharmaceuticals Name Members of New Board of Directors, to Serve Upon Completion of Merger
    The Female Health Company and Aspen Park Pharmaceuticals Name Members of New Board of Directors, to Serve Upon Completion of MergerAugust 11th, 2016
  • Localized Prostate Cancer
    Localized Prostate CancerJune 13th, 2018

Other Languages

  • German, Portuguese, Spanish

Hospital Affiliations

External Links

Dr. Mario Eisenberger, Dr. Mario Eisenberger, MD, Dr. M Eisenberger, Dr. Mario Alfredo Eisenberger